Table 1 Patients’ biological and clinical parameters.
From: Immuno-regulatory malignant B cells contribute to Chronic Lymphocytic Leukemia progression
Numbers of CLL samples | n = 97 |
|---|---|
Sex (Female/Male ratio) | 34 / 63 (35.05% / 64.95%) |
Age (years) | Mean: 66.91 |
Median: 66 | |
IGHV mutational status | |
Unmutated: | 39 (40.20%) |
Mutated: | 55 (56.70%) |
NA: | 3 (3.10%) |
Binet Stage at the experiment time (number and %) | |
A: | 61/97 (62.89%) |
B: | 14/97 (14.43%) |
C: | 10/97 (10.30%) |
ND: | 12/97 (12.37%) |
Treatment (more than 2 years prior to the experiment time) | |
Cohort #1 (n = 28) | |
Cluster 1 (n = 17; 4 NA) | 2/13 (15.38%) |
Cluster 2 (n = 11; 1 NA) | 5/10 (50.00%) |
Need of Treatment | |
Cohort #2 (n = 23) | |
Cluster 1 (n = 15) | 5/15 (33.33%) |
Cluster 2 (n = 8) | 5/8 (62.50%) |
